Muratore, Andrea

A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 939

Stromal contribution to the colorectal cancer transcriptome

Isella, C., Terrasi, A., Bellomo, S. E., Petti, C., Galatola, G., Muratore, A., Mellano, A., Senetta, R., Cassenti, A., Sonetto, C., et al. (2015) · Nature Genetics

Cancer Cells and MetastasisColorectal Cancer Treatments and Studies

Cited by 640

The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer

Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 479

Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas

Migliardi, G., Sassi, F., Torti, D., Galimi, F., Zanella, E. R., Buscarino, M., Ribero, D., Muratore, A., Massucco, P., Pisacane, A., et al. (2012) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesPI3K/AKT/mTOR signaling in cancer

Cited by 191